Study of Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis (JIA)
Public ClinicalTrials.gov record NCT00048542. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Efficacy, and Pharmacokinetics of the Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis
Study identification
- NCT ID
- NCT00048542
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Abbott
- Industry
- Enrollment
- 171 participants
Conditions and interventions
Conditions
Interventions
- Double-Blind Adalimumab/Placebo + MTX Biological
- Double-Blind Adalimumab/Placebo Biological
- OLE BSA Adalimumab +/- MTX Drug
- OLE FD Adalimumab +/- MTX Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 4 Years to 17 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2002
- Primary completion
- Dec 31, 2004
- Completion
- May 31, 2010
- Last update posted
- Aug 21, 2011
2002 – 2010
United States locations
- U.S. sites
- 15
- U.S. states
- 13
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site Ref # / Investigator 45524 | Birmingham | Alabama | 35294-3300 | — |
| Site Reference ID/Investigator# 2235 | Los Angeles | California | 90027 | — |
| Site Reference ID/Investigator# 642 | Stanford | California | 94305 | — |
| Site Reference ID/Investigator# 638 | Delray Beach | Florida | 33406 | — |
| Site Ref # / Investigator 45543 | St. Petersburg | Florida | 33701 | — |
| Site Reference ID/Investigator# 640 | Chicago | Illinois | 60649 | — |
| Site Reference ID/Investigator# 644 | Kansas City | Kansas | 66160 | — |
| Site Reference ID/Investigator# 641 | Minneapolis | Minnesota | 55455 | — |
| Site Reference ID/Investigator# 645 | Omaha | Nebraska | 68131 | — |
| Site Reference ID/Investigator# 2501 | Livingston | New Jersey | 07039 | — |
| Site Ref # / Investigator 45542 | New Hyde Park | New York | 11040 | — |
| Site Ref # / Investigator 45544 | Chapel Hill | North Carolina | 27599-7220 | — |
| Site Reference ID/Investigator# 386 | Columbus | Ohio | 43205 | — |
| Site Ref # / Investigator 45525 | Salt Lake City | Utah | 84312-2206 | — |
| Site Reference ID/Investigator# 406 | Norfolk | Virginia | 23507 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00048542, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 21, 2011 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00048542 live on ClinicalTrials.gov.